AR044802A1 - Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos - Google Patents
Sales farmaceuticamente aceptables, de derivados de acidos carboxilicosInfo
- Publication number
- AR044802A1 AR044802A1 ARP040102112A ARP040102112A AR044802A1 AR 044802 A1 AR044802 A1 AR 044802A1 AR P040102112 A ARP040102112 A AR P040102112A AR P040102112 A ARP040102112 A AR P040102112A AR 044802 A1 AR044802 A1 AR 044802A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- acid derivatives
- carboxyl acid
- dyslipidemias
- Prior art date
Links
- -1 CARBOXYL Chemical class 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- VFYAWARECOZRBD-VWLOTQADSA-N (2s)-2-ethoxy-3-[4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]phenyl]propanoic acid Chemical compound C=1C=C(C[C@H](OCC)C(O)=O)C=CC=1OCC(=O)N(CCCCCC)CCC1=CC=CC=C1 VFYAWARECOZRBD-VWLOTQADSA-N 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 159000000003 magnesium salts Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se refiere a una sal de calcio o magnesio de ácido (2S)-2-etoxi-3-(4-{2[hexil(2-feniletil)amino]-2-oxoetoxi]fenil)propanoico, a procesos para preparar dichos compuestos, utilidad en el tratamiento de afecciones clínicas que incluyen trastornos en los lípidos (dislipidemias) asociados o no a la resistencia a la insulina y otras manifestaciones del síndrome metabólico, a métodos para su uso terapéutico y a composiciones farmacéuticas que las contienen.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0314136.3A GB0314136D0 (en) | 2003-06-18 | 2003-06-18 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044802A1 true AR044802A1 (es) | 2005-10-05 |
Family
ID=27636795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102112A AR044802A1 (es) | 2003-06-18 | 2004-06-17 | Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20060194879A1 (es) |
| EP (1) | EP1638921A1 (es) |
| JP (1) | JP3836498B1 (es) |
| KR (1) | KR20060017646A (es) |
| CN (1) | CN1805922A (es) |
| AR (1) | AR044802A1 (es) |
| AU (1) | AU2004247611A1 (es) |
| BR (1) | BRPI0411455A (es) |
| CA (1) | CA2527608A1 (es) |
| CO (1) | CO5650229A2 (es) |
| GB (1) | GB0314136D0 (es) |
| IL (1) | IL172168A0 (es) |
| IS (1) | IS8232A (es) |
| MX (1) | MXPA05013713A (es) |
| NO (1) | NO20055923L (es) |
| RU (1) | RU2005138369A (es) |
| SA (1) | SA04250170B1 (es) |
| TW (1) | TW200503678A (es) |
| UY (1) | UY28371A1 (es) |
| WO (1) | WO2004110985A1 (es) |
| ZA (1) | ZA200510199B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0229931D0 (en) * | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| CA2489834C (en) | 2002-06-20 | 2006-10-03 | Astrazeneca Ab | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| WO2007004957A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | Novel crystalline form |
| AR055073A1 (es) * | 2005-07-11 | 2007-08-01 | Astrazeneca Ab | Agentes terapeuticos |
| FR2903985B1 (fr) | 2006-07-24 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2904316B1 (fr) | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. |
| UY30648A1 (es) * | 2006-10-20 | 2008-05-02 | Janssen Pharmaceutica Nv | Formas salinas de compuestos de benzotienilo sustituido |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL351898A1 (en) * | 1999-04-06 | 2003-06-30 | Sankyo Co | O-substituted derivatives of carboxylic acids |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
-
2003
- 2003-06-18 GB GBGB0314136.3A patent/GB0314136D0/en not_active Ceased
-
2004
- 2004-06-09 TW TW093116599A patent/TW200503678A/zh unknown
- 2004-06-16 BR BRPI0411455-8A patent/BRPI0411455A/pt not_active IP Right Cessation
- 2004-06-16 RU RU2005138369/04A patent/RU2005138369A/ru not_active Application Discontinuation
- 2004-06-16 CA CA002527608A patent/CA2527608A1/en not_active Abandoned
- 2004-06-16 KR KR1020057024066A patent/KR20060017646A/ko not_active Withdrawn
- 2004-06-16 SA SA04250170A patent/SA04250170B1/ar unknown
- 2004-06-16 US US10/560,127 patent/US20060194879A1/en not_active Abandoned
- 2004-06-16 EP EP04736956A patent/EP1638921A1/en not_active Withdrawn
- 2004-06-16 WO PCT/SE2004/000965 patent/WO2004110985A1/en not_active Ceased
- 2004-06-16 JP JP2006517040A patent/JP3836498B1/ja not_active Expired - Fee Related
- 2004-06-16 AU AU2004247611A patent/AU2004247611A1/en not_active Abandoned
- 2004-06-16 MX MXPA05013713A patent/MXPA05013713A/es not_active Application Discontinuation
- 2004-06-16 CN CNA2004800168384A patent/CN1805922A/zh active Pending
- 2004-06-17 AR ARP040102112A patent/AR044802A1/es not_active Application Discontinuation
- 2004-06-17 UY UY28371A patent/UY28371A1/es not_active Application Discontinuation
-
2005
- 2005-11-24 IL IL172168A patent/IL172168A0/en unknown
- 2005-12-13 NO NO20055923A patent/NO20055923L/no not_active Application Discontinuation
- 2005-12-14 ZA ZA200510199A patent/ZA200510199B/en unknown
- 2005-12-28 CO CO05130776A patent/CO5650229A2/es unknown
-
2006
- 2006-01-13 IS IS8232A patent/IS8232A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY28371A1 (es) | 2005-01-31 |
| RU2005138369A (ru) | 2007-07-27 |
| IS8232A (is) | 2006-01-13 |
| GB0314136D0 (en) | 2003-07-23 |
| US20060194879A1 (en) | 2006-08-31 |
| BRPI0411455A (pt) | 2006-07-18 |
| NO20055923L (no) | 2006-01-06 |
| IL172168A0 (en) | 2009-02-11 |
| CN1805922A (zh) | 2006-07-19 |
| ZA200510199B (en) | 2006-12-27 |
| SA04250170B1 (ar) | 2007-10-29 |
| EP1638921A1 (en) | 2006-03-29 |
| CA2527608A1 (en) | 2004-12-23 |
| KR20060017646A (ko) | 2006-02-24 |
| JP3836498B1 (ja) | 2006-10-25 |
| TW200503678A (en) | 2005-02-01 |
| AU2004247611A1 (en) | 2004-12-23 |
| MXPA05013713A (es) | 2006-06-27 |
| WO2004110985A1 (en) | 2004-12-23 |
| JP2006527767A (ja) | 2006-12-07 |
| CO5650229A2 (es) | 2006-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200701913A1 (ru) | Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом | |
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| CO6341548A2 (es) | Nuevos lipidos que contienen azufre para el uso como suplemento alimenticio o como medicamento | |
| SG10201400685SA (en) | Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia | |
| CR9703A (es) | Derivados de pirazolona | |
| CR9667A (es) | Derivados de benzamida y usos relacionados con los mismos | |
| AR080491A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
| ECSP088405A (es) | Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer | |
| ES2496669T3 (es) | Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen | |
| ECSP10010265A (es) | Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8 dihidro-9h-purin-9-il)propil](3-morfolin-4 ilpropil)amino]metil}fenil) | |
| UY32691A (es) | Compuestos de 1h-imidazo-[4,5-c]-quinolinona | |
| AR069508A1 (es) | Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento | |
| JP2014218522A5 (es) | ||
| AR058163A1 (es) | Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona | |
| AR063538A1 (es) | Tratamiento de la enfermedad de parkinson | |
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| CY1120852T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας | |
| AR060568A1 (es) | Acidos bifenilcarboxilicos substituidos y sus derivados | |
| ES2531516T3 (es) | Uso de escina | |
| AR029412A1 (es) | Forma cristalina | |
| AR073265A1 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
| UY29065A1 (es) | Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos. | |
| CO5650229A2 (es) | Sales farmaceuticamente utiles de derivados de acido carboxilico | |
| PE20030277A1 (es) | Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |